Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals announced that its CEO, Dr. Howie McKibbon, will present at the Canaccord Drug and Device Healthcare Conference in Noosa. The presentation aims to engage institutional investors and is part of a broader investor roadshow hosted by Canaccord Genuity. This event is significant as it provides Botanix an opportunity to showcase its FDA-approved product, Sofdra®, and potentially strengthen its market position and investor relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US. The company has received FDA approval for its lead product, Sofdra®, which is the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel solution for patients with this condition.
Average Trading Volume: 8,802,218
Technical Sentiment Signal: Sell
Current Market Cap: A$285.7M
See more data about BOT stock on TipRanks’ Stock Analysis page.